THERAPEUTIC SLTNS INTL - TSOI STOCK NEWS

On May 17, 2021, Therapeutic Solutions International (OTC Markets: TSOI) announced preclinical data showing that low doses of FDA-cleared interleukin-2 effectively reduce depression in an animal model. The study highlights a novel cellular mechanism and may facilitate quicker clinical development given interleukin-2’s existing regulatory approval for cancer treatment. President Kalina O'Connor emphasized the significance of this research in addressing rising suicide rates, while Vice President Famela Ramos noted the importance of their innovative approach in neurology. The company aims to combat depression with a focus on immune modulation.

On May 10, 2021, Therapeutic Solutions International (TSOI) announced promising preclinical data from its subsidiary, Campbell Neurosciences, regarding the use of mesenchymal stem cell therapy for schizophrenia. The study showed that intravenous doses of stem cells and modified monocytes can mitigate behavioral issues and promote neurogenesis. The company aims to file an Investigational New Drug (IND) application with the FDA for this treatment in patients unresponsive to current therapies. This research may redefine schizophrenia treatment, with potential implications for patient outcomes and investor interests.

Therapeutic Solutions International, Inc. (OTC Markets: TSOI) announced the FDA's acknowledgment of its IND application for a clinical trial aimed at treating chronic traumatic encephalopathy (CTE). This marks a significant milestone as the FDA recognizes CTE as a valid disease indication. The FDA has requested minor adjustments to the trial protocol, focusing on manufacturing, delivery, and patient monitoring. The company believes it is the only one pursuing regenerative therapeutics for CTE through regulatory channels, aiming to address the health issues faced by affected individuals.

Therapeutic Solutions International (OTC Markets: TSOI) announced new findings on April 26, 2021, showcasing a synergy between its StemVacs-V iPSC derived immunotherapy and low-dose cyclophosphamide. In animal studies, this combination led to significant tumor reductions in lung, brain, and skin cancers, alongside increased immune cell infiltration. The results indicate that lower chemotherapy doses can retain efficacy, marking a potential breakthrough in cancer treatment. Company executives highlighted the importance of this synergy for advancing cancer therapeutics and improving patient outcomes.

Therapeutic Solutions International (OTC: TSOI) announced significant findings regarding NarcoStem™, a biologic derived from umbilical cord blood, showcasing its role in stimulating Brain Derived Neurotrophic Factor (BDNF) production. This advancement is crucial for treating drug addiction and repairing brain damage. The company emphasizes the importance of BDNF in combating addiction and improving mental health. Positive preliminary data supports the efficacy of NarcoStem™ in addressing neurological issues, especially in post-COVID patients. The ongoing collaboration with Campbell Neurosciences aims to accelerate therapeutic development.

Therapeutic Solutions International (OTC: TSOI) announced a new patent filing for a cord blood-based intranasal product aimed at reducing adverse mental effects from opioid addiction. Preclinical studies demonstrated its efficacy in suppressing TLR4, a protein linked to opioid addiction, and reducing brain inflammation. The company emphasizes that this innovative approach addresses the root causes of addiction, unlike existing treatments. The development marks a significant step towards potential clinical applications in treating opioid addiction.

On April 5, 2021, Therapeutic Solutions International (OTC Markets: TSOI) announced the completion of a 30-patient trial for the Kaihani Score, a blood-based test for gambling addiction. The trial revealed significant differences in neuromodulatory protein levels among healthy individuals and those with moderate to severe gambling addiction. The company aims to develop interventions for mental illnesses by analyzing these proteins. TSOI is currently engaging with regulators to initiate pivotal registration trials for both the Campbell Score and Kaihani Score, addressing a gambling addiction epidemic costing the economy $54 billion annually.

Therapeutic Solutions International (OTC Markets: TSOI) has announced new data supporting its innovative immunotherapy derived from inducible pluripotent stem cells (iPSC). This approach aims to selectively destroy cancer-associated blood vessels by harnessing the alpha1,3-galactosyltransferase enzyme. Unlike previous therapies, which activate 1 in 1,000,000 immune cells, this method stimulates up to 1 in 100. The technology promises a consistent cell therapy product, crucial for collaborations with Big Pharma and regulatory progress.

Therapeutic Solutions International, Inc. (OTC Markets: TSOI) announced the filing of a patent for a unique cell designed to train the immune system to target cancerous blood vessels while preserving healthy vessels. This innovation builds on prior findings showing StemVacs' ability to suppress new blood vessel formation. The company's new product, StemVacs-V™, is a chimeric cell derived from engineered iPSC cells, demonstrating selective killing of malignant blood vessels, which could offer significant therapeutic potential.